Amyris, Inc. (NASDAQ:AMRS) Director Frank Kung Sells 1,385,000 Shares of Stock

Amyris, Inc. (NASDAQ:AMRSGet Rating) Director Frank Kung sold 1,385,000 shares of the stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $4.20, for a total transaction of $5,817,000.00. Following the completion of the sale, the director now owns 458,591 shares of the company’s stock, valued at approximately $1,926,082.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Frank Kung also recently made the following trade(s):

  • On Monday, September 19th, Frank Kung sold 1,080,676 shares of Amyris stock. The stock was sold at an average price of $3.80, for a total transaction of $4,106,568.80.

Amyris Stock Performance

Shares of NASDAQ AMRS opened at $3.95 on Tuesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.13 and a current ratio of 1.66. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -2.62 and a beta of 1.36. The business’s 50-day simple moving average is $2.73 and its 200-day simple moving average is $3.03. Amyris, Inc. has a 52 week low of $1.47 and a 52 week high of $15.12.

Amyris (NASDAQ:AMRSGet Rating) last announced its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The company had revenue of $65.20 million during the quarter, compared to analysts’ expectations of $81.53 million. During the same period last year, the firm posted ($0.16) EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities research analysts expect that Amyris, Inc. will post -1.11 earnings per share for the current fiscal year.

Institutional Trading of Amyris

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Amyris by 2.7% in the 1st quarter. BlackRock Inc. now owns 21,667,736 shares of the biotechnology company’s stock worth $94,470,000 after acquiring an additional 575,957 shares during the period. Farallon Capital Management LLC lifted its position in shares of Amyris by 55.9% in the 1st quarter. Farallon Capital Management LLC now owns 16,931,427 shares of the biotechnology company’s stock worth $73,821,000 after acquiring an additional 6,071,616 shares during the period. Edmond DE Rothschild Holding S.A. lifted its position in shares of Amyris by 52.6% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 6,965,700 shares of the biotechnology company’s stock worth $12,887,000 after acquiring an additional 2,401,900 shares during the period. State of Michigan Retirement System lifted its position in shares of Amyris by 35.9% in the 2nd quarter. State of Michigan Retirement System now owns 6,545,000 shares of the biotechnology company’s stock worth $12,108,000 after acquiring an additional 1,730,000 shares during the period. Finally, Pinnacle Associates Ltd. lifted its position in shares of Amyris by 0.8% in the 1st quarter. Pinnacle Associates Ltd. now owns 4,656,745 shares of the biotechnology company’s stock worth $20,303,000 after acquiring an additional 38,860 shares during the period. Institutional investors own 43.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AMRS. Roth Capital downgraded shares of Amyris from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 10th. Piper Sandler raised their target price on Amyris from $2.50 to $4.00 and gave the company a “neutral” rating in a report on Monday. Finally, JPMorgan Chase & Co. began coverage on Amyris in a research note on Friday, June 24th. They set a “neutral” rating for the company.

Amyris Company Profile

(Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Recommended Stories

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.